PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9526554-1	1998	A family of sequence-related 2"-aminopyrimidine, 2"-hydroxylpurine aptamers, developed by oligonucleotide-based combinatorial chemistry, SELEX (systematic evolution of ligand by exponential enrichment) technology, binds human nonpancreatic secretory phospholipase A2 (hnps-PLA2) with nanomolar affinities and inhibits enzymatic activity.	2-aminopyrimidine	29-47	phospholipase A2 group IIA	Homo sapiens	226-266
11512149-2	2001	Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG.	2-aminopyrimidine	13-28	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	109-112
11512149-2	2001	Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG.	2-aminopyrimidine	13-28	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	159-164
11512149-2	2001	Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG.	2-aminopyrimidine	13-28	platelet derived growth factor subunit B	Homo sapiens	166-175
11604388-7	2001	An aminopyrimidine, PNU 112455A, was identified in a screen for inhibitors of cdk2.	2-aminopyrimidine	3-18	cyclin dependent kinase 2	Homo sapiens	78-82
9526554-1	1998	A family of sequence-related 2"-aminopyrimidine, 2"-hydroxylpurine aptamers, developed by oligonucleotide-based combinatorial chemistry, SELEX (systematic evolution of ligand by exponential enrichment) technology, binds human nonpancreatic secretory phospholipase A2 (hnps-PLA2) with nanomolar affinities and inhibits enzymatic activity.	2-aminopyrimidine	29-47	phospholipase A2 group IIA	Homo sapiens	273-277
9513604-2	1998	The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined.	2-aminopyrimidine	73-88	immunoglobulin heavy diversity 2-15	Homo sapiens	32-48
35219044-8	2022	Our findings suggested that a 2-aminopyrimidine-based LSD1 inhibitor deserves further investigation as a treatment for LSD1-overexpressing cancer.	2-aminopyrimidine	30-47	lysine demethylase 1A	Homo sapiens	54-58
34819010-4	2022	Based on our previous studies, we assumed that a hybrid of aminopyrimidine derivatives as EGFR inhibitors and benzocheromen derivatives as cytotoxic agents can induce apoptosis in EGFR positive cancer cells.	2-aminopyrimidine	59-74	epidermal growth factor receptor	Homo sapiens	90-94
34819010-4	2022	Based on our previous studies, we assumed that a hybrid of aminopyrimidine derivatives as EGFR inhibitors and benzocheromen derivatives as cytotoxic agents can induce apoptosis in EGFR positive cancer cells.	2-aminopyrimidine	59-74	epidermal growth factor receptor	Homo sapiens	180-184
35219044-0	2022	Design, synthesis and biological evaluation of 2-aminopyrimidine-based LSD1 inhibitors.	2-aminopyrimidine	47-64	lysine demethylase 1A	Homo sapiens	71-75
35219044-3	2022	Then, a series of 2-aminopyrimidine derivatives were designed and synthesized as LSD1 inhibitors, and their structure-activity relationships were studied.	2-aminopyrimidine	18-35	lysine demethylase 1A	Homo sapiens	81-85
34534838-0	2021	Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno (3,2-c)pyridine as potent EGFR inhibitors.	2-aminopyrimidine	47-62	epidermal growth factor receptor	Homo sapiens	136-140
34534838-1	2021	To resolve the problem of drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno (3,2-c)pyridine side chains (according to the binding mode of AZD9291 to EGFRT790M) for use as EGFRL858R/T790M kinase inhibitors.	2-aminopyrimidine	207-222	epidermal growth factor receptor	Homo sapiens	52-84
34534838-1	2021	To resolve the problem of drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno (3,2-c)pyridine side chains (according to the binding mode of AZD9291 to EGFRT790M) for use as EGFRL858R/T790M kinase inhibitors.	2-aminopyrimidine	207-222	epidermal growth factor receptor	Homo sapiens	86-90
35138851-0	2022	Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.	2-aminopyrimidine	18-35	FMS-like tyrosine kinase 3	Mus musculus	51-55
35138851-0	2022	Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.	2-aminopyrimidine	18-35	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	101-106
33689071-4	2021	We tested the potential to inhibit the transcription of individual Oct-1 isoforms using the GSK3 kinase inhibitor CHIR, an aminopyrimidine derivative.	2-aminopyrimidine	123-138	POU class 2 homeobox 1 S homeolog	Xenopus laevis	67-72
33217405-2	2021	In a recent paper, we showed the difference between the first stage of the one-substrate and the two-substrate transketolase reactions - the possibility of transfer of glycolaldehyde formed as a result of cleavage of the donor substrate from the thiazole ring of thiamine diphosphate to its aminopyrimidine ring through the tricycle formation stage, which is necessary for binding and splitting the second molecule of donor substrate [O.N.	2-aminopyrimidine	291-306	transketolase	Homo sapiens	111-124
33859803-0	2021	Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.	2-aminopyrimidine	52-69	fibroblast growth factor receptor 4	Homo sapiens	76-81
33859803-2	2021	Herein we report a series of selective 2-aminopyrimidine-based fibroblast growth factor receptor 4 (FGFR4) inhibitors exploring different types of cysteine-targeting warheads.	2-aminopyrimidine	39-56	fibroblast growth factor receptor 4	Homo sapiens	63-98
33859803-2	2021	Herein we report a series of selective 2-aminopyrimidine-based fibroblast growth factor receptor 4 (FGFR4) inhibitors exploring different types of cysteine-targeting warheads.	2-aminopyrimidine	39-56	fibroblast growth factor receptor 4	Homo sapiens	100-105
33946516-4	2021	The current study shows that an aminopyrimidine derivative compound (CHIR99021) induces the inhibition of GSK-3beta in cultured late EPCs.	2-aminopyrimidine	32-47	glycogen synthase kinase 3 alpha	Homo sapiens	106-115
33404239-3	2021	Herein, we report the discovery of a potent and novel OGA inhibitor, compound 5i, comprising an aminopyrimidine scaffold, identified by virtual screening based on multiple methodologies combining structure-based and ligand-based approaches, followed by sequential optimization with a focus on ligand lipophilicity efficiency.	2-aminopyrimidine	96-111	O-GlcNAcase	Homo sapiens	54-57
33217405-6	2021	Therefore, a significant decrease in the reaction rate of the one-substrate transketolase reaction compared to the two-substrate reaction is due to the stage of transferring the first glycolaldehyde molecule from the thiazole ring to the aminopyrimidine ring of thiamine diphosphate.	2-aminopyrimidine	238-253	transketolase	Homo sapiens	76-89
32574211-4	2020	We discovered an aminopyrimidine small molecule, 2062, that had no direct antimycobacterial activity, but synergized with rifampin to reduce bacterial burden in Mtb infected macrophages and mice and also dampened lung immunopathology.	2-aminopyrimidine	17-32	non-SMC condensin II complex, subunit G2	Mus musculus	161-164
32884210-0	2020	Molecular docking of C-Jun-N-Terminal Kinase (Jnk) with amino-pyrimidine derivatives.	2-aminopyrimidine	56-72	mitogen-activated protein kinase 8	Homo sapiens	21-44
32884210-0	2020	Molecular docking of C-Jun-N-Terminal Kinase (Jnk) with amino-pyrimidine derivatives.	2-aminopyrimidine	56-72	mitogen-activated protein kinase 8	Homo sapiens	46-49
32884210-1	2020	It is of interest to document the molecular docking of C-Jun-N-Terminal Kinase (Jnk) (known structure with PDB ID: 1PMN) with amino-pyrimidine derivatives in the context of Alzheimer"s Disease (AD).	2-aminopyrimidine	126-142	mitogen-activated protein kinase 8	Homo sapiens	55-78
32884210-1	2020	It is of interest to document the molecular docking of C-Jun-N-Terminal Kinase (Jnk) (known structure with PDB ID: 1PMN) with amino-pyrimidine derivatives in the context of Alzheimer"s Disease (AD).	2-aminopyrimidine	126-142	mitogen-activated protein kinase 8	Homo sapiens	80-83
32884210-2	2020	We report the optimal binding features (binding energy, interacting residues, inter atomic hydrogen bonding patterns) of 11 amino-pyrimidine derivatives with Jnk for further consideration.	2-aminopyrimidine	124-140	mitogen-activated protein kinase 8	Homo sapiens	158-161
32877741-1	2020	Hybridisation of amino-pyrimidine based SYK inhibitors (e.g. 1a) with previously reported diamine-based SYK inhibitors (e.g. TAK-659) led to the identification and optimisation of a novel pyrimidine-based series of potent and selective SYK inhibitors, where the original aminomethylene group was replaced by a 3,4-diaminotetrahydropyran group.	2-aminopyrimidine	17-33	spleen associated tyrosine kinase	Homo sapiens	40-43
33142418-0	2020	Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).	2-aminopyrimidine	33-50	Janus kinase 2	Homo sapiens	79-93
33142418-0	2020	Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).	2-aminopyrimidine	33-50	Janus kinase 2	Homo sapiens	95-99
33142418-0	2020	Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).	2-aminopyrimidine	33-50	fms related receptor tyrosine kinase 3	Homo sapiens	105-131
33142418-0	2020	Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).	2-aminopyrimidine	33-50	fms related receptor tyrosine kinase 3	Homo sapiens	133-137
33142418-1	2020	Herein, with the help of computer-aided drug design (CADD), we describe the structure-based rational drug design, structure-activity relationships, and synthesis of a series of 2-aminopyrimidine derivatives that inhibit both JAK2 and FLT3 kinases.	2-aminopyrimidine	177-194	Janus kinase 2	Homo sapiens	225-229
33142418-1	2020	Herein, with the help of computer-aided drug design (CADD), we describe the structure-based rational drug design, structure-activity relationships, and synthesis of a series of 2-aminopyrimidine derivatives that inhibit both JAK2 and FLT3 kinases.	2-aminopyrimidine	177-194	fms related receptor tyrosine kinase 3	Homo sapiens	234-238
32891858-0	2020	Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity.	2-aminopyrimidine	49-64	solute carrier family 9 member A6	Homo sapiens	88-92
32891858-0	2020	Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity.	2-aminopyrimidine	49-64	ETS transcription factor ERG	Homo sapiens	109-113
31303989-0	2019	Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors.	2-aminopyrimidine	0-15	galectin 3	Homo sapiens	55-65
31926936-1	2020	BX795, a small molecule with an aminopyrimidine backbone, is a potent ATP-competitive inhibitor of phosphoinositide-dependent kinase 1 (PDK1) and TANK-binding kinase 1 (TBK1).	2-aminopyrimidine	32-47	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	99-134
31926936-1	2020	BX795, a small molecule with an aminopyrimidine backbone, is a potent ATP-competitive inhibitor of phosphoinositide-dependent kinase 1 (PDK1) and TANK-binding kinase 1 (TBK1).	2-aminopyrimidine	32-47	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	136-140
31926936-1	2020	BX795, a small molecule with an aminopyrimidine backbone, is a potent ATP-competitive inhibitor of phosphoinositide-dependent kinase 1 (PDK1) and TANK-binding kinase 1 (TBK1).	2-aminopyrimidine	32-47	TANK-binding kinase 1	Mus musculus	146-167
31926936-1	2020	BX795, a small molecule with an aminopyrimidine backbone, is a potent ATP-competitive inhibitor of phosphoinositide-dependent kinase 1 (PDK1) and TANK-binding kinase 1 (TBK1).	2-aminopyrimidine	32-47	TANK-binding kinase 1	Mus musculus	169-173
31806538-0	2020	Structural optimization of aminopyrimidine-based CXCR4 antagonists.	2-aminopyrimidine	27-42	C-X-C motif chemokine receptor 4	Homo sapiens	49-54
31806538-1	2020	Structural optimization of aminopyrimidine-based CXCR4 antagonists is reported.	2-aminopyrimidine	27-42	C-X-C motif chemokine receptor 4	Homo sapiens	49-54
31303989-4	2019	Here, we report aminopyrimidine-derivatised galactosides as good galectin-3 inhibitors with affinities down to 1.7 muM and a more than 300-fold selectivity over galectin-1.	2-aminopyrimidine	16-31	galectin 3	Homo sapiens	65-75
31303989-4	2019	Here, we report aminopyrimidine-derivatised galactosides as good galectin-3 inhibitors with affinities down to 1.7 muM and a more than 300-fold selectivity over galectin-1.	2-aminopyrimidine	16-31	galectin 1	Homo sapiens	161-171
31303989-7	2019	Hence, combining an aminopyrimidine motif with a phenyl alpha-thiogalactoside motif offers an attractive route towards highly selective galectin-3 inhibitors.	2-aminopyrimidine	20-35	galectin 3	Homo sapiens	136-146
30667164-1	2019	A series of novel aminopyrimidine and diaminopyrimidine derivatives were designed and optimized to improve their potency and permeability relative to lead compound 1 (IC50  = 37.4 muM), which was discovered in a previous virtual screening.	2-aminopyrimidine	18-33	latexin	Homo sapiens	180-183
29301478-0	2019	New substituted aminopyrimidine derivatives as BACE1 inhibitors: in silico design, synthesis and biological assays.	2-aminopyrimidine	16-31	beta-secretase 1	Homo sapiens	47-52
30646877-7	2019	An appropriate cavity and a hydrophobic nodule were also present in TKTL1/2, into which the diphosphate group fitted, and that was implicated in aminopyrimidine and thiazole ring binding in TKT, respectively.	2-aminopyrimidine	145-160	transketolase like 1	Homo sapiens	68-75
30646877-7	2019	An appropriate cavity and a hydrophobic nodule were also present in TKTL1/2, into which the diphosphate group fitted, and that was implicated in aminopyrimidine and thiazole ring binding in TKT, respectively.	2-aminopyrimidine	145-160	transketolase	Homo sapiens	68-71
29301478-1	2019	We report in this work new substituted aminopyrimidine derivatives acting as inhibitors of the catalytic site of BACE1.	2-aminopyrimidine	39-54	beta-secretase 1	Homo sapiens	113-118
30204041-0	2018	Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study.	2-aminopyrimidine	38-54	epidermal growth factor receptor	Homo sapiens	81-85
30145688-2	2018	Aim of the present study was to investigate the role of structurally related H4R ligands of the aminopyrimidine class with different efficacies and functionalities (neutral antagonist ST-994, partial agonist ST-1006, inverse agonist ST-1012, and partial inverse agonist ST-1124) on croton oil-induced ear edema and pruritus in mice.	2-aminopyrimidine	96-111	histamine receptor H4	Mus musculus	77-80
29871845-2	2018	A potent Pim kinase inhibitor 7f, derived from meridianin C, was further optimized by the replacement of 2-aminopyrimidine with substituted benzene.	2-aminopyrimidine	105-122	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	9-12
28881253-6	2017	Replacement of ring B with a 2-amino-pyrimidine moiety led to compound 12 with an increase of affinity and selectivity for the adenosine A2A receptor.	2-aminopyrimidine	29-47	adenosine A2a receptor	Rattus norvegicus	127-149
29494843-2	2018	Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed.	2-aminopyrimidine	83-98	C-X-C motif chemokine receptor 4	Homo sapiens	46-51
29394041-0	2018	Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Abeta-Fibrinogen Interaction and Abeta-Induced Contact System Activation.	2-aminopyrimidine	0-15	amyloid beta precursor protein	Homo sapiens	63-68
28853575-4	2017	The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance.	2-aminopyrimidine	68-83	epidermal growth factor receptor	Homo sapiens	107-111
28483702-1	2017	As a part of our extensive structure-activity relationship study of anti-inflammatory heterocycles, a novel series of 67 polysubstituted 2-aminopyrimidines was prepared bearing one (at the C-4 position of the pyrimidine ring) or two (in the C-4 and C-6 positions) (hetero)aryl substituents attached directly through the C-C bond.	2-aminopyrimidine	137-155	complement C4A (Rodgers blood group)	Homo sapiens	189-192
26898335-1	2016	Structure based design of a novel class of aminopyrimidine MTH1 (MutT homolog 1) inhibitors is described.	2-aminopyrimidine	43-58	nudix hydrolase 1	Homo sapiens	59-63
27517803-0	2016	Optimization and biological evaluation of aminopyrimidine-based IkappaB kinase beta inhibitors with potent anti-inflammatory effects.	2-aminopyrimidine	42-57	inhibitor of kappaB kinase beta	Mus musculus	64-83
27517803-2	2016	In this study, we have successfully developed a structure-activity relationship (SAR) profile of the aminopyrimidine-based IKKbeta inhibitors through the structure-based design strategy to improve the physicochemical properties and cellular activity in terms of the anti-inflammatory effects.	2-aminopyrimidine	101-116	inhibitor of kappaB kinase beta	Mus musculus	123-130
27549813-1	2016	Here is reported the development of a novel scoring function that performs remarkably well at identifying the native binding pose of a subset of HSP90 inhibitors containing aminopyrimidine or resorcinol based scaffolds.	2-aminopyrimidine	173-188	heat shock protein 90 alpha family class A member 1	Homo sapiens	145-150
27549813-5	2016	These results indicate that the specific residues considered by PocketScore are determinant to properly model the interaction between HSP90 and its subset of inhibitors containing aminopyrimidine or resorcinol based scaffolds.	2-aminopyrimidine	180-195	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
27133739-1	2016	The present in vitro experiments demonstrate inhibitory effects of polysubstituted 2-aminopyrimidines on high output production of nitric oxide (NO) and prostaglandin E2 (PGE2) stimulated by interferon-gamma and lipopolysaccharide (LPS) in peritoneal macrophages of mouse and rat origin.	2-aminopyrimidine	83-101	interferon gamma	Mus musculus	191-207
28580438-1	2017	Profiling of the kinase-binding capabilities of an aminopyrimidine analogue detected in a cellular screen of the St. Jude small-molecule collection led to the identification of a novel series of FMS-like tyrosine kinase 3 (FLT3) inhibitors.	2-aminopyrimidine	51-66	fms related receptor tyrosine kinase 3	Homo sapiens	195-221
28580438-1	2017	Profiling of the kinase-binding capabilities of an aminopyrimidine analogue detected in a cellular screen of the St. Jude small-molecule collection led to the identification of a novel series of FMS-like tyrosine kinase 3 (FLT3) inhibitors.	2-aminopyrimidine	51-66	fms related receptor tyrosine kinase 3	Homo sapiens	223-227
28523108-0	2017	2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.	2-aminopyrimidine	0-17	fibroblast growth factor receptor 4	Homo sapiens	47-82
28523108-0	2017	2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.	2-aminopyrimidine	0-17	fibroblast growth factor receptor 4	Homo sapiens	84-89
28523108-1	2017	A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors.	2-aminopyrimidine	12-29	fibroblast growth factor receptor 4	Homo sapiens	92-97
28221788-0	2017	Substituted 2-Aminopyrimidines Selective for alpha7-Nicotinic Acetylcholine Receptor Activation and Association with Acetylcholine Binding Proteins.	2-aminopyrimidine	12-30	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	52-84
28221788-3	2017	Initial screening of a series of over 50 newly characterized 2-aminopyrimidines with affinity for AChBP showed only two to be agonists on the alpha7-nAChR below 10 muM concentration.	2-aminopyrimidine	61-79	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	149-154
27660691-2	2016	An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM.	2-aminopyrimidine	49-64	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	80-89
26898335-1	2016	Structure based design of a novel class of aminopyrimidine MTH1 (MutT homolog 1) inhibitors is described.	2-aminopyrimidine	43-58	nudix hydrolase 1	Homo sapiens	65-79
26115573-2	2015	Previous efforts identified a series of aminopyrimidine IRAK4 inhibitors that possess good potency, but modest kinase selectivity.	2-aminopyrimidine	40-55	interleukin 1 receptor associated kinase 4	Homo sapiens	56-61
26445848-1	2015	The present study sought to determine the anti-tumor effects of OXA-11, a potent, novel small-molecule amino pyrimidine inhibitor (1.2 pM biochemical IC(50)) of focal adhesion kinase (FAK).	2-aminopyrimidine	103-119	PTK2 protein tyrosine kinase 2	Mus musculus	161-182
26445848-1	2015	The present study sought to determine the anti-tumor effects of OXA-11, a potent, novel small-molecule amino pyrimidine inhibitor (1.2 pM biochemical IC(50)) of focal adhesion kinase (FAK).	2-aminopyrimidine	103-119	PTK2 protein tyrosine kinase 2	Mus musculus	184-187
26451770-0	2015	Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.	2-aminopyrimidine	31-47	epidermal growth factor receptor	Homo sapiens	75-107
26451770-2	2015	Here, a series of novel aminopyrimidines bearing a hydrazone moiety were identified as potent and selective EGFR inhibitors.	2-aminopyrimidine	24-40	epidermal growth factor receptor	Homo sapiens	108-112
23347159-1	2013	BACKGROUND AND PURPOSE: The recently proposed binding mode of 2-aminopyrimidines to the human (h) histamine H4 receptor suggests that the 2-amino group of these ligands interacts with glutamic acid residue E182(5.46) in the transmembrane (TM) helix 5 of this receptor.	2-aminopyrimidine	62-80	histamine receptor H4	Homo sapiens	98-119
25278747-0	2014	Drug-likeness approach of 2-aminopyrimidines as histamine H3 receptor ligands.	2-aminopyrimidine	26-44	histamine receptor H3	Homo sapiens	48-69
25317974-10	2014	Compounds with a variety of headgroups were docked into the PI3Kalpha and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements.	2-aminopyrimidine	102-117	mechanistic target of rapamycin kinase	Homo sapiens	74-78
23668417-4	2013	In the series of 2-aminopyrimidines, the introduction of an additional 2-aminopyrimidine moiety in combination with the appropriate linker lead to bispyrimidines displaying pKi values for binding the human H4R up to 8.2.	2-aminopyrimidine	17-35	histamine receptor H4	Homo sapiens	206-209
23671017-1	2013	Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK 304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile.	2-aminopyrimidine	88-103	kinase insert domain receptor	Homo sapiens	139-145
23668417-4	2013	In the series of 2-aminopyrimidines, the introduction of an additional 2-aminopyrimidine moiety in combination with the appropriate linker lead to bispyrimidines displaying pKi values for binding the human H4R up to 8.2.	2-aminopyrimidine	17-34	histamine receptor H4	Homo sapiens	206-209
23352510-0	2013	Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.	2-aminopyrimidine	15-31	mitogen-activated protein kinase 8	Rattus norvegicus	46-69
23352510-0	2013	Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.	2-aminopyrimidine	15-31	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
23352510-1	2013	A series of amino-pyrimidines was developed based upon an initial kinase cross-screening hit from a CDK2 program.	2-aminopyrimidine	12-29	cyclin dependent kinase 2	Rattus norvegicus	100-104
21981714-2	2011	mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.	2-aminopyrimidine	140-157	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22742537-0	2012	Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors.	2-aminopyrimidine	61-79	advanced glycosylation end product-specific receptor	Mus musculus	99-143
22742537-0	2012	Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors.	2-aminopyrimidine	61-79	advanced glycosylation end product-specific receptor	Mus musculus	145-149
22030027-0	2011	Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kbeta) inhibitors with selectivity over PI3Kalpha.	2-aminopyrimidine	17-32	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	71-79
22030027-0	2011	Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kbeta) inhibitors with selectivity over PI3Kalpha.	2-aminopyrimidine	17-32	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	114-123
22030027-3	2011	When incorporated with the phenyl ring on sulfonamide moiety, aminopyrimidine analogs showed good potency on PI3Kbeta and selectivity over PI3Kalpha.	2-aminopyrimidine	62-77	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	109-117
22030027-3	2011	When incorporated with the phenyl ring on sulfonamide moiety, aminopyrimidine analogs showed good potency on PI3Kbeta and selectivity over PI3Kalpha.	2-aminopyrimidine	62-77	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	139-148
22335519-3	2012	Through structure-based design, we discovered a new class of highly potent aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles.	2-aminopyrimidine	75-90	Braf transforming gene	Mus musculus	97-102
22290078-2	2012	Aminopyrimidines including compound 32a were identified to display good PrCP inhibitory activity (32a, IC(50)=43 nM) and impressive ability to penetrate brain in mice (brain/plasma ratio: 1.4).	2-aminopyrimidine	0-16	prolylcarboxypeptidase (angiotensinase C)	Mus musculus	72-76
22202103-6	2012	Among the diverse chemical structures of the H4R antagonists described a 2-aminopyrimidine scaffold is repeatedly found.	2-aminopyrimidine	73-90	histamine receptor H4	Homo sapiens	45-48
21875802-4	2011	This approach quickly identified 2-aminotriazine and 2-aminopyrimidine derivatives as specific ligands to Hsp90 with high ligand efficiency.	2-aminopyrimidine	53-70	heat shock protein 90 alpha family class A member 1	Homo sapiens	106-111
21861543-2	2011	It is an aminopyrimidine-based, high-affinity inhibitor of the tyrosine kinase activity of BCR-ABL.	2-aminopyrimidine	9-24	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	91-98
19947601-0	2010	Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.	2-aminopyrimidine	75-90	mitogen-activated protein kinase 8	Rattus norvegicus	91-114
21684737-0	2011	Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.	2-aminopyrimidine	30-48	cyclin dependent kinase 1	Homo sapiens	52-56
21684737-0	2011	Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.	2-aminopyrimidine	30-48	cyclin dependent kinase 2	Homo sapiens	61-65
20171098-0	2010	Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.	2-aminopyrimidine	11-29	histamine receptor H4	Mus musculus	33-54
20171098-1	2010	Three novel series of histamine H(4) receptor (H(4)R) antagonists containing the 2-aminopyrimidine motif are reported.	2-aminopyrimidine	81-98	histamine receptor H4	Mus musculus	22-52
21623630-3	2011	Additionally, an iodine atom or various aryl groups were introduced at the C-5 position of the 2-aminopyrimidine ring.	2-aminopyrimidine	95-112	complement C5	Homo sapiens	75-78
21666838-3	2011	To fill this void we developed an aminopyrimidine JNK inhibitor (SR-3306) that reduced the loss of dopaminergic cell bodies in the SNpc and their terminals in the striatum produced by unilateral injection of 6-hydroxydopamine (6-OHDA) into the nigrostriatal pathway.	2-aminopyrimidine	34-49	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
20385788-2	2010	We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets.	2-aminopyrimidine	22-37	Janus kinase 1	Mus musculus	74-78
20385788-2	2010	We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets.	2-aminopyrimidine	22-37	Janus kinase 2	Mus musculus	80-84
20385788-2	2010	We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets.	2-aminopyrimidine	22-37	tyrosine kinase 2	Mus musculus	90-107
20385788-2	2010	We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets.	2-aminopyrimidine	22-37	tyrosine kinase 2	Mus musculus	109-113
19947601-0	2010	Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.	2-aminopyrimidine	75-90	mitogen-activated protein kinase 8	Rattus norvegicus	116-119
19947601-2	2010	The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice.	2-aminopyrimidine	62-78	mitogen-activated protein kinase 8	Mus musculus	149-152
19920925-5	2009	The development of novel agents designed to overcome IM resistance, while still primarily targeted on BCR-ABL, led to the creation of the high affinity aminopyrimidine inhibitor, nilotinib.	2-aminopyrimidine	152-167	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	102-109
19856966-1	2009	A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt beta-catenin cellular messaging system.	2-aminopyrimidine	156-173	catenin beta 1	Rattus norvegicus	205-217
19147349-0	2009	Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.	2-aminopyrimidine	44-59	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76
17519960-5	2007	Herein we demonstrate a dose-dependent, reversible inhibition of ABCG2-mediated Hoechst 33342 dye efflux in primary human and murine HSC by both imatinib and nilotinib (AMN107), a novel aminopyrimidine inhibitor of BCR-ABL.	2-aminopyrimidine	186-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-70
18811133-1	2008	A series of 2-aminopyrimidines was synthesized as ligands of the histamine H4 receptor (H4R).	2-aminopyrimidine	12-30	histamine receptor H4	Homo sapiens	65-86
18956997-6	2008	It represents an aminopyrimidine derivative of imatinib with approximately 30 times more potency in vitro against imatinib-sensitive BCR-ABL-expressing cell lines and activity against 32 of 33 point mutations conferring resistance to imatinib.	2-aminopyrimidine	17-32	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	133-140
18501602-0	2008	Synthesis and structure-activity relationship of aminopyrimidine IKK2 inhibitors.	2-aminopyrimidine	49-64	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	65-69
17613767-1	2007	The aminopyrimidine inhibitor AMN107 (Nilotinib) was rationally designed to antagonize the aberrant tyrosine kinase activity of Bcr-Abl-positive cells.	2-aminopyrimidine	4-19	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	128-135
17459703-0	2007	Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.	2-aminopyrimidine	21-37	mitogen-activated protein kinase 8	Homo sapiens	47-70
17459703-0	2007	Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.	2-aminopyrimidine	21-37	mitogen-activated protein kinase 8	Homo sapiens	72-75
17459703-1	2007	The development of a series of novel aminopyrimidines as inhibitors of c-Jun N-terminal kinases is described.	2-aminopyrimidine	37-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-76
17131463-0	2007	Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.	2-aminopyrimidine	12-28	vascular endothelial growth factor A	Homo sapiens	52-56
17131463-1	2007	X-ray structures from CDK2-aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework.	2-aminopyrimidine	27-42	cyclin dependent kinase 2	Homo sapiens	22-26
17131463-1	2007	X-ray structures from CDK2-aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework.	2-aminopyrimidine	119-134	cyclin dependent kinase 2	Homo sapiens	22-26
17131463-4	2007	Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF-RTKs.	2-aminopyrimidine	12-28	cyclin dependent kinase 12	Homo sapiens	72-87
16000593-0	2005	AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.	2-aminopyrimidine	16-31	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	45-52
16750629-3	2006	Among the pyrimido-pyrimidones the emergence of two sub-types of analogs-C7-amino-pyrimidines such as 24 and C7-amino-piperidines such as 42-characterized with good p38 inhibition and better off-target profiles in terms of ion channel activities was significant.	2-aminopyrimidine	76-93	mitogen-activated protein kinase 14	Homo sapiens	165-168
16078266-0	2005	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.	2-aminopyrimidine	16-31	contactin associated protein 1	Homo sapiens	45-49
16078266-0	2005	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.	2-aminopyrimidine	16-31	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	50-57
14625007-3	2003	Thereafter, protected amino acids were coupled iteratively by the DCC method, commencing at the amino group of the aminopyrimidine unit.	2-aminopyrimidine	115-130	DCC netrin 1 receptor	Homo sapiens	66-69
14623876-8	2004	The mechanistic implications of the active site arrangement are discussed, including the potential role of the aminopyrimidine ring of the ThP2.	2-aminopyrimidine	111-126	GLI family zinc finger 2	Homo sapiens	139-143
14658877-3	2003	The structure determination of a substrate-bound DPD species, Zn2(DPD)(2-aminopyrimidine) (2), completes a set of structurally homologous zinc(II) porphyrin host and host-guest complexes, which offer a direct structural comparison for the Pacman effect upon substrate complexation.	2-aminopyrimidine	71-89	dihydropyrimidine dehydrogenase	Homo sapiens	49-52
14658877-3	2003	The structure determination of a substrate-bound DPD species, Zn2(DPD)(2-aminopyrimidine) (2), completes a set of structurally homologous zinc(II) porphyrin host and host-guest complexes, which offer a direct structural comparison for the Pacman effect upon substrate complexation.	2-aminopyrimidine	71-89	dihydropyrimidine dehydrogenase	Homo sapiens	66-69
12693972-8	2003	According to our hypothesis, the induced absorption band is that of the imino form of ThDP resulting from three contributing features of the ThDP binding site of transketolase: the relative hydrophobicity of this site, hydrogen bonding of the N1;-atom of the ThDP aminopyrimidine ring to Glu418, and base stacking interactions between the aminopyrimidine ring of ThDP and Phe445.	2-aminopyrimidine	264-279	transketolase	Homo sapiens	162-175